Analysis of clinical characteristics and risk factors for infection in patients with multiple myeloma treated with bortezomib

JIANG Wenting; ZHOU Jie; LYU Bo; SHI Aiming; LI Bingzong; PAN Jie

doi:10.6039/j.issn.1001-0408.2026.07.20

您当前的位置：

首页 >

文章列表页 >

Analysis of clinical characteristics and risk factors for infection in patients with multiple myeloma treated with bortezomib

更新时间：2026-07-16

- Analysis of clinical characteristics and risk factors for infection in patients with multiple myeloma treated with bortezomib
- ZHONGGUO YAOFANG Vol. 37, Issue 7, Pages: 942-948(2026)
- 作者机构：
  
  1.苏州大学附属第二医院药学部，江苏苏州　215004
  2.苏州大学附属第二医院血液科，江苏苏州　215004
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.07.20
  CLC： R969.3;R979.1
- Received：30 November 2025，
  
  Revised：2025-12-21，
  
  Accepted：18 March 2026，
  
  Published：15 April 2026
- 稿件说明：
移动端阅览
蒋文婷,周洁,吕波,等.硼替佐米治疗多发性骨髓瘤患者发生感染的临床特征及危险因素分析 [J].中国药房,2026,37(07):942-948.

JIANG Wenting,ZHOU Jie,LYU Bo,et al.Analysis of clinical characteristics and risk factors for infection in patients with multiple myeloma treated with bortezomib[J].ZHONGGUO YAOFANG,2026,37(07):942-948.
蒋文婷,周洁,吕波,等.硼替佐米治疗多发性骨髓瘤患者发生感染的临床特征及危险因素分析 [J].中国药房,2026,37(07):942-948. DOI： 10.6039/j.issn.1001-0408.2026.07.20.

JIANG Wenting,ZHOU Jie,LYU Bo,et al.Analysis of clinical characteristics and risk factors for infection in patients with multiple myeloma treated with bortezomib[J].ZHONGGUO YAOFANG,2026,37(07):942-948. DOI： 10.6039/j.issn.1001-0408.2026.07.20.

摘要

目的

研究多发性骨髓瘤（MM）患者使用硼替佐米治疗后发生感染的临床特征及潜在危险因素。

方法

回顾性收集2021年10月至2025年2月苏州大学附属第二医院血液科接受以硼替佐米为基础治疗方案的MM患者的临床资料，主要包括人口学特征、MM的疾病特征、用药方案、感染发生情况及相应处理措施、预防性用药等；对MM合并感染的潜在危险因素进行单因素及多因素Logistic回归分析。

结果

在284例使用硼替佐米的MM患者中，132例患者至少发生了1次感染（占46.5%），感染类型以呼吸道感染和消化道感染为主。单因素分析结果显示，初诊年龄、病理分型、骨髓抑制分级是MM患者发生感染的影响因素（

＜0.05）。进一步分析两种主要感染类型的影响因素，结果显示，性别、初诊年龄、病理分型、治疗方案、吸烟史是MM患者发生呼吸道感染的影响因素（

＜0.05）；BMI、病理分型、治疗方案、骨髓抑制分级是MM患者发生消化道感染的影响因素（

＜0.05）。多因素Logistic回归分析结果显示，年龄≥70岁、治疗前存在Ⅳ级骨髓抑制为MM患者发生感染的危险因素，而IgG-λ型为MM患者发生感染的保护因素（

＜0.05）。

结论

以硼替佐米为基础治疗方案的MM患者感染发生率较高，并以呼吸道和消化道感染为主；初诊年龄、骨髓抑制分级、病理分型为MM患者发生感染的影响因素。

Abstract

OBJECTIVE

To study the clinical characteristics and potential risk factors for infection in patients with multiple myeloma （MM） following treatment with bortezomib.

METHODS

Clinical data were retrospectively collected from MM patients who received bortezomib-based treatment regimens at the Department of Hematology， the Second Affiliated Hospital of Soochow University， from October 2021 to February 2025. The collected data primarily included demographic characteristics， disease characteristics of MM， treatment regimens， occurrence of infections and corresponding management measures， and prophylactic medication use. Univariate and multivariate Logistic regression analyses were conducted to identify potential risk factors for MM complicated with infection.

RESULTS

Among the 284 MM patients treated with bortezomib， 132 patients （46.5%） experienced at least one infection. The predominant types of infections were respiratory tract infections and gastrointestinal infections. Univariate analysis showed that age at initial diagnosis， pathological classification， and grade of myelosuppression were influencing factors for infection in MM patients （

＜0.05）. Further analysis of influencing factors for the two main types of infections revealed that sex， age at initial diagnosis， pathological classification， treatment regimen， and smoking history were influencing factor

s for respiratory tract infections in MM patients （

＜0.05）； BMI， pathological classification， treatment regimen， and grade of myelosuppression were influencing factors for gastrointestinal infections in MM patients （

＜0.05）. Multivariate Logistic regression analysis indicated that age≥70 years and the presence of grade Ⅳ myelosuppression before treatment were risk factors for infection in MM patients， while the IgG-λ type was a protective factor against infection （

＜0.05）.

CONCLUSIONS

The incidence of infection is relatively high in MM patients receiving bortezomib-based treatment regimens， with respiratory and gastrointestinal infections being the most common. Age at initial diagnosis， grade of myelosuppression， and pathological classification are influencing factors for infection in MM patients.

关键词

Keywords

references

KUMAR S K ， RAJKUMAR V ， KYLE R A ， et al . Multiple myeloma [J ] . Nat Rev Dis Primers ， 2017 ， 3 ： 17046 .

叶宇凡，张林娜，陈晓玲，等 . 真实世界国产硼替佐米治疗初诊多发性骨髓瘤疗效评价 [J ] . 临床血液学杂志， 2021 ， 34 （ 5 ）： 327 - 331 .

王璐，崔森，冀林华 . 蛋白酶体抑制剂在复发和难治性多发性骨髓瘤中的研究进展 [J ] . 实用癌症杂志， 2020 ， 35 （ 2 ）： 343 - 345 .

NANDAKUMAR B ， BINDER M ， DISPENZIERI A ， et al . Continued improvement in survival in multiple myeloma （MM） including high-risk patients [J ] . J Clin Oncol ， 2019 ， 37 （ Suppl.15 ）： 8039 .

FUJIWARA M ， UCHIDA M ， ENDO M ， et al . Cardiac adverse events associated with multiple myeloma patients treated with proteasome inhibitors [J ] . Oncology ， 2023 ， 101 （ 5 ）： 343 - 348 .

杨丽萍，卢馨怡，王鑫炜，等 . 新药时代多发性骨髓瘤住院患者感染的临床特征及危险因素分析 [J ] . 中国实验血液学杂志， 2024 ， 32 （ 6 ）： 1790 - 1797 .

李高，张启科，魏小芳，等 . 多发性骨髓瘤患者使用硼替佐米化疗期间发生肺部感染的临床危险因素分析 [J ] . 中国实验血液学杂志， 2021 ， 29 （ 1 ）： 152 - 157 .

李高，张启科，魏小芳，等 . 硼替佐米治疗多发性骨髓瘤患者发生带状疱疹危险因素分析 [J ] . 中国实验血液学杂志， 2020 ， 28 （ 6 ）： 1972 - 1976 .

中国医师协会血液科医师分会，中华医学会血液学分会 . 中国多发性骨髓瘤诊治指南：2024年修订 [J ] . 中华内科杂志， 2024 ， 63 （ 12 ）： 1186 - 1195 .

JOHN L ， MIAH K ， BENNER A ， et al . Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma [J ] . Front Oncol ， 2023 ， 13 ： 1078725 .

黄芮 . 国产和原研硼替佐米治疗初诊多发性骨髓瘤的疗效与安全性观察 [D ] . 合肥：安徽医科大学， 2021 .

彭婷 . 多发性骨髓瘤感染的临床分析及机器学习构建感染预测模型 [D ] . 长沙：中南大学， 2023 .

BICI A ， PIANKO M J ， NACHAR V R . Incidence and risk factors for bacterial infection using bortezomib，lenalidomide，and dexamethasone （RVd） in newly diagnosed multiple myeloma [J ] . Leuk Lymphoma ， 2023 ， 64 （ 2 ）： 407 - 414 .

范丽，马艳萍，晁瑶，等 . 老年多发性骨髓瘤肾损害患者的临床特征、预后及疗效分析 [J ] . 中国实验血液学杂志， 2021 ， 29 （ 1 ）： 145 - 151 .

LIU K ， YIN Y F ， ZHOU X F ， et al . Expression and correlation of IL-2，IL-10 and TNF-α in patients with multiple myeloma-infected herpes zoster treated by bortezomib-containing regimen [J ] . Am J Transl Res ， 2021 ， 13 （ 12 ）： 13732 - 13740 .

BLANCO B ， PÉREZ-SIMÓN J A ， SÁNCHEZ-ABARCA L I ， et al . Treatment with bortezomib of human CD4 + T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population [J ] . Haematologica ， 2009 ， 94 （ 7 ）： 975 - 983 .

NENCIONI A ， SCHWARZENBERG K ， BRAUER K M ， et al . Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation [J ] . Blood ， 2006 ， 108 （ 2 ）： 551 - 558 .

HYUN S Y ， HAN S H ， KIM S J ， et al . Pretreatment lymphopenia，poor performance status，and early courses of therapy are risk factors for severe bacterial infection in patients with multiple myeloma during treatment with bortezomib-based regimens [J ] . J Korean Med Sci ， 2016 ， 31 （ 4 ）： 510 - 518 .

LI J ， LI Y ， HUANG B H ， et al . Drug-induced modulation of T lymphocytes as a potential mechanism of susceptibility to infections in patients with multiple myeloma during bortezomib therapy [J ] . Cell Biochem Biophys ， 2015 ， 71 （ 1 ）： 457 - 464 .

ZHANG L ， QI J Y ， QI P J ， et al . Comparison among immunologically different subtypes of 595 untreated multiple myeloma patients in northern China [J ] . Clin Lymphoma Myeloma Leuk ， 2010 ， 10 （ 3 ）： 197 - 204 .

SILVA L M ， KIM T S ， MOUTSOPOULOS N M . Neutrophils are gatekeepers of mucosal immunity [J ] . Immunol Rev ， 2023 ， 314 （ 1 ）： 125 - 141 .

KUMAR V . Innate lymphoid cell and adaptive immune cell cross-talk：a talk meant not to forget [J ] . J Leukoc Biol ， 2020 ， 108 （ 1 ）： 397 - 417 .

BRUSCIA E M ， BONFIELD T L . Update on innate and adaptive immunity in cystic fibrosis [J ] . Clin Chest Med ， 2022 ， 43 （ 4 ）： 603 - 615 .

RUHNAU D ， HESS C ， DOUPOVEC B ， et al . Deepoxy-deoxynivalenol （DOM-1），a derivate of deoxynivalenol （DON），exhibits less toxicity on intestinal barrier function， Campylobacter jejuni colonization and translocation in broiler chickens [J ] . Gut Pathog ， 2021 ， 13 （ 1 ）： 44 .

段燕春，王灿飞 . 多发性骨髓瘤合并肺部感染的临床特征及危险因素分析 [J ] . 护理实践与研究， 2020 ， 17 （ 1 ）： 52 - 53 .

Views

186

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of the incidence and associated factors of cyclosporine-associated acute kidney injury in hospitalized patients based on real-world data

Rapid health technology assessment of carfilzomib in the treatment of multiple myeloma

Real-world study on the application and influencing factors of SGLT-2i in patients with heart failure with preserved ejection fraction

Analysis of risk factors for serum digoxin concentration exceeding the warning threshold and construction of prediction model

Analysis of risk factors and construction of risk prediction model for batroxobin-related severe hypofibrinogenemia

Related Author

DOU Yaqing

LAO Jiahui

WANG Xue

SUN Yanying

HUANG Xin

LI Hanbing

LI Xiao

FENG Zhen

Related Institution

Healthcare Big Data Center， the First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital

Dept. of Clinical Pharmacy， the First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital

College of Pharmaceutical Sciences， Zhejiang University of Technology

Dept. of Pharmacy， the Affiliated Hospital of Xuzhou Medical University

Dept. of Cardiology， Chongqing University Central Hospital

⁰